"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 8 | 8 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 7 | 8 |
| 2006 | 2 | 5 | 7 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 6 | 7 |
| 2009 | 0 | 10 | 10 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 13 | 13 |
| 2013 | 0 | 7 | 7 |
| 2014 | 5 | 23 | 28 |
| 2015 | 3 | 13 | 16 |
| 2016 | 6 | 14 | 20 |
| 2017 | 5 | 13 | 18 |
| 2018 | 0 | 8 | 8 |
| 2019 | 2 | 9 | 11 |
| 2020 | 1 | 17 | 18 |
| 2021 | 2 | 8 | 10 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 3 | 6 |
| 2025 | 0 | 3 | 3 |
| 2026 | 1 | 8 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Weiss GJ. Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States. PLoS One. 2026; 21(10):e0353373.
-
Joshi M, Kim K, Pickard AS, Sharp LK, Gerber BS, Touchette DR. Long-term cost-effectiveness of a mobile health intervention delivered by clinical pharmacists and community health workers for type 2 diabetes management in urban African American and Latinx populations. Am J Health Syst Pharm. 2026 04 07; 83(8):423-435.
-
Toan ATN, Phung TL, Tran-Duy A, Minh HV. Cost-Effectiveness of Add-On Ivabradine Versus Standard Pharmacotherapy in the Treatment of Heart Failure in Vietnam: An Analysis From a Health System Perspective. Value Health Reg Issues. 2026 Sep; 55:101594.
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
-
Montano-Campos JF, Adair JE, Basu A, Kyeyune RB, Bayigga L, Kityo-Mutuluuza C, Hansen R. Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda's context. Gene Ther. 2026 03; 33(2):109-117.
-
Généreux P, Reynolds MR, Kelley MA, Thompson C, Baron SJ. Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States. Value Health. 2026 Jul; 29(7):1171-1179.
-
Gottimukkala KSV, Lane DD, Cunningham R, Malik HS, Jwa Y, Cassidy ME, Castelli JMP, Enstrom MR, Poljakov K, Gastelum G, Ho SH, Tassa C, Adair JE. CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCs. Gene Ther. 2026 03; 33(2):188-202.
-
Driver L, Walsh CD, Schissel C, Meguerdichian DA, Duggan NM, Baugh CW, Goldsmith AJ. Utilizing an ultrasound-guided nerve block for management of sciatica in the ED: A national simulation-based cost savings analysis. Am J Emerg Med. 2026 Mar; 101:135-140.
-
Juvekar P, Whitmore R. Cost Effectiveness in the Treatment of Lumbar Spondylolisthesis. Neurosurg Clin N Am. 2026 Jan; 37(1):93-102.
-
Choi SE, Simon L. Projected Outcomes of Removing Fluoride From US Public Water Systems. JAMA Health Forum. 2025 05 02; 6(5):e251166.